

Introduction

David S. Hui^{1,2}, Giovanni A. Rossi³ and Sebastian L. Johnston⁴

Viral respiratory tract infections are important and common causes of morbidity and mortality worldwide. Over the past two decades, several novel viral respiratory infections with epidemic potential that threaten global health security have emerged. Human cases of the highly pathogenic avian influenza A(H5N1) were initially detected in Hong Kong in 1997, before spreading to other parts of Asia, the Middle East, Europe and Africa, with a case fatality rate close to 60%. Influenza A(H1N1)pdm09 virus first emerged in 2009 as a novel swine-origin strain, which rapidly led to a pandemic and has remained a common circulating strain in many parts of the world. Human infections with the novel avian influenza A(H7N9) virus were first reported in mainland China in March 2013 and the infection has since spread to Hong Kong and Taiwan. Avian influenza A(H5N1) and A(H7N9) viruses have continued to circulate widely in some poultry populations and infect humans sporadically; sporadic human cases of avian A(H5N6), A(H10N8) and A(H6N1) have also emerged.

In March 2003, the World Health Organization (WHO) issued a global alert about an emerging SARS caused by a novel CoV, which rapidly spread from mainland China *via* Hong Kong to at least 29 countries/regions and finally ended in July 2003, with 8096 probable cases and 774 deaths. Since its first discovery in a patient who died of severe pneumonia in Saudi Arabia in 2012, MERS-CoV has spread to 26 countries. The mortality rates of MERS-CoV infection are high, especially in those with comorbid disease.

In addition to the threat of novel CoV and avian influenza viruses, the burden of the common respiratory viruses, such as seasonal influenza, RSV and human rhinoviruses (HRV), on healthcare utilisation remains high, and yet is also a largely unmet medical need. This highlights the urgent need for developing more effective therapies in order to reduce the morbidity and mortality associated with novel threats, as well as the regular offenders.

The Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) (<http://www.prepare-europe.eu/>) is an European Union funded network aiming to harmonise large-scale clinical research studies on infectious diseases, and provide real-time evidence for clinical management of patients and for informing public health responses. To advance our understanding of the clinical, epidemiological and scientific aspects of important respiratory viruses and facilitate planning of research studies on emerging

¹Dept of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. ²Stanley Ho Center for Emerging Infectious Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. ³Dept of Pediatrics, Pulmonary and Allergy Disease Units, Istituto G. Gaslini, Genoa, Italy. ⁴National Heart & Lung Institute, Imperial College London, London, UK.

Correspondence: David S. Hui, Dept of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. E-mail: dschui@cuhk.edu.hk

Copyright ©ERS 2016. Print ISBN: 978-1-84984-069-9. Online ISBN: 978-1-84984-070-5. Print ISSN: 2312-508X. Online ISSN: 2312-5098.

infectious diseases, this *ERS Monograph* aims to provide an up-to-date and comprehensive overview of SARS, MERS and other viral respiratory infections, including seasonal influenza, avian influenza, RSV and HRV through six chapters written by authoritative experts from around the globe. We are most grateful to all the authors for their enormous contribution to this excellent book. We believe the selected topics will be of immense interest to all clinicians and scientists in the field.

Disclosures: S.L. Johnston reports receiving grants and personal fees from Centocor, Sanofi Pasteur, GSK, Chiesi, Boehringer Ingelheim and Novartis. He has also received personal fees from Grünenthal. He has received grants, personal fees and holds shares in Synairgen. In addition, S.L. Johnston has the following licensed patents. Blair ED, Killington RA, Rowlands DJ, Clarke NJ, Johnston SL. Transgenic animal models of HRV with human ICAM-1 sequences. UK patent application no. 02 167 29.4, 18 July 2002 and International patent application No. PCT/EP2003/007939, 17 July 2003; Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. UK patent application no. GB 0405634.7, 12 March 2004; Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. International patent application no. PCT/GB05/50031, 12 March 2004; Wark PA, Johnston SL, Holgate ST, Davies DE. The use of interferon lambda for the treatment and prevention of virally-induced exacerbation in asthma and chronic pulmonary obstructive disease. UK patent application no. 0518425.4, 9 September 2005; Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases. US patent application - 11/517,763, patent no. 7569216, national phase of PCT/GB2005/050031, 04 August 2009; Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-virus therapy for respiratory diseases. European patent number 1734987, 5 May 2010; Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases (IFN β therapy) Hong Kong patent number 1097181, 31 August 2010; Wark PA, Johnston SL, Holgate ST, Davies DE. Anti-virus therapy for respiratory diseases (IFN β therapy). Japanese patent number 4807526, 26 August 2011; Wark PA, Johnston SL, Holgate ST, Davies DE. Interferon-beta for anti-Virus therapy for respiratory diseases. New Hong Kong - Divisional patent application no. 11100187.0, 10 January 2011. S.L. Johnston also has the following patent pending. Burdin N, Almond J, Lecouturier V, Girerd-Chambaz Y, Guy B, Bartlett N, Walton R, McLean G, Glanville N, Johnston SL. Induction of cross-reactive cellular response against rhinovirus antigens. European Patent Number 13305152, 4 April 2013.